| Description: |
Robert Sandhaus,1 Charlie Strange,2 Glenda Stone,3 M Chris Runken,3 Christopher M Blanchette,4 Reuben Howden5 1Division of Pulmonary, Critical Care and Sleep Medicine, National Jewish Health, Denver, CO, USA; 2Department of Pulmonary and Critical Care Medicine, Medical University of South Carolina, Charleston, SC, USA; 3Global Health Economics & Outcomes Research, Grifols Shared Services of North America, Inc, Research Triangle Park, NC, USA; 4Department of Public Health Sciences, College of Health and Human Services, University of North Carolina at Charlotte, Charlotte, NC, USA; 5Department of Kinesiology, College of Health and Human Services, University of North Carolina at Charlotte, Charlotte, NC, USACorrespondence: Glenda StoneGlobal Health Economics & Outcomes Research, Grifols Shared Services of North America, Inc, 79 T.W. Alexander Dr, 4101 Research Commons, Research Triangle Park, NC 27709, USATel +1 (919)316-6415Email glenda.stone@grifols.comIntroduction: Alpha-1 antitrypsin deficiency (AATD) is often not identified in patients with chronic obstructive pulmonary disease (COPD) until advanced stages of disease, despite the availability of genetic testing. While clinical practice guidelines provide recommendations on patients who should be tested, more refined algorithms are needed to identify COPD patients who are likely candidates for AATD testing and to prevent delays in diagnosis and treatment. The objective of this study was to identify comorbid associations with AATD among patients diagnosed with COPD in the United States.Methods: Using data from the 2012– 2017 PharMetrics Plus Administrative Claims Database and 2011– 2014 Medicare Fee for Service 5% Sample, patients with COPD (ICD-9-CM: 491.xx, 492.xx, or 496, ICD-10-CM J41, J42, J43, J44) and AATD (ICD-9-CM: 273.4, ICD-10-CM: E88.01) were identified. Patient demographic and diagnostic characteristics were assessed. Logistic regression models were developed to identify significant predictors of AATD.Results: A ... |